Evidence map›Paper›PMID 41498919›Full record

ArticleBreast cancer (Tokyo, Japan)2026

Prognostic relevance of specific TIL (CD4+, CD8+, and FOXP3 + T-cell infiltrates) in triple-negative breast cancer: short- and long-term outcomes.

Olga Caramelo, Vânia Almeida, Ana Fidalgo, Augusta Cipriano, Teresa Almeida-Santos

Abstract read
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Olga CarameloDepartment of Gynecology, Unidade Local de Saúde de Coimbra, Coimbra, Portugal. olgalgcaramelo@gmail.com.ORCID http://orcid.org/0000-0003-0825-6732
Vânia AlmeidaDepartment of Pathology, Unidade Local de Saúde de Coimbra, Coimbra, Portugal.
Ana Fidalgo, Immunethep, Cantanhede, Portugal.
Augusta CiprianoDepartment of Pathology, Unidade Local de Saúde de Coimbra, Coimbra, Portugal.
Teresa Almeida-SantosDepartment of Gynecology, Unidade Local de Saúde de Coimbra, Coimbra, Portugal.ORCID http://orcid.org/0000-0001-7423-2996

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer is a heterogeneous malignant disease that remains as one of the most prevalent cancers globally. Triple negative breast cancer (TNBC) accounts for 15% of the total of breast cancers and presents high tumor immunogenicity and a tumor microenvironment that plays a critical role in disease progression and patient outcomes.

methodsThis study evaluated a total of 30 tissue samples from female patients with TNBC, to characterize specific immune cells within the tumor tissue and investigate their relationship with short (pathological complete response, pCR), long (disease-free survival, DFS) and clinical outcomes. Tumor-infiltrating lymphocytes (TIL) were assessed by immunohistochemistry (IHC) on tissue microarrays (TMA), complemented by digital analysis for standardized quantification.

resultsOur results highlight the influence of CD4⁺ T cells on short-term outcomes: high CD4⁺ T-cell levels were significantly associated with achieving pCR. High CD8⁺ T-cell levels were also significantly associated with axillary lymph node negativity.Regarding long-term outcomes, higher CD4⁺, CD8⁺ and FOXP3⁺ T-cell levels showed a non-significant tendency toward improved DFS.

conclusionsThese findings suggest that high levels of CD4 + T cells and CD8 + T cells are positive predictors of immediate, long-term prognosis and clinical prognosis in patients with TNBC. This study enhances the understanding on the immunological interests in specific subtypes of TIL and identifies potential biomarkers that could drive advancements in precision medicine for breast cancer management.

Indexed as

CD4-Positive T-LymphocytesCD8-Positive T-LymphocytesLymphocytes, Tumor-InfiltratingTriple Negative Breast NeoplasmsAdultAgedBiomarkers, TumorDisease-Free SurvivalFemaleForkhead Transcription FactorsHumansMiddle AgedPathologic Complete ResponsePrognosisTissue Array AnalysisTumor MicroenvironmentBiomarkers, TumorForkhead Transcription FactorsFOXP3 protein, humanBreast cancerCD4 + T cellsCD8 + T cellsFOXP3 + cellsImmune cellsT cellsTILT regs

Identifiers

PMID41498919
PMCPMC12960379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.